Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGI-134 in Unresectable/Metastatic Solid Tumours
NCT03593226Phase 2Completed
- Sponsor
- Agalimmune Ltd
- Start
- Nov 2018
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands, Therapeutic Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of AGI-134 in solid tumor, sponsored by Agalimmune Ltd. Started Nov 2018; status: completed.
02
Drugs
AGI-134
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03593226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03593226.